查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842329

美國次世代定序市場：市場規模、佔有率和趨勢分析（按技術、產品、應用、工作流程和最終用途分類），細分市場預測（2025-2033 年）

U.S. Next Generation Sequencing Market Size, Share & Trends Analysis Report By Technology, By Product, By Application, By Workflow (Pre-sequencing, Sequencing, Data Analysis), By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國次世代定序市場摘要

據估計，美國次世代定序市場在 2024 年的價值為 37.6 億美元，預計到 2033 年將達到 167.5 億美元，2025 年至 2033 年的複合年成長率為 18.1%。

該國強大的製藥、生物技術和研究機構正在推動次世代定序(NGS) 技術的發展。市場成長的驅動力來自不斷增加的研發項目，這些項目主要集中在癌症、感染疾病和精準醫療領域。此外，基因檢測技術的進步也促進了 NGS 在臨床實驗室中的應用，用於診斷罕見疾病和指南精準醫療。

癌症和遺傳性疾病發生率不斷上升

美國癌症、遺傳性疾病和複雜遺傳疾病的日益普遍是推動新一代定序（NGS）市場發展的關鍵因素。次世代定序能夠早期檢測基因突變和染色體異常，從而實現及時診斷和製定個人化治療方案。在腫瘤學領域，NGS有助於識別腫瘤特異性突變，對患者進行分層以進行標靶治療，並監測疾病進展和復發。它還能提供罕見疾病和遺傳疾病的全面基因組資訊，支持精準診斷、帶因者篩檢和家族風險評估。醫護人員和病患對基因檢測益處的認知不斷提高，也進一步促進了NGS的普及應用。

此外，新生兒篩檢計畫、產前基因檢測和大規模人群基因組學研究等措施正在推動NGS在臨床和研究領域的應用。對精準醫療日益成長的需求以及對基因和基因組研究投入的增加，凸顯了NGS在改善患者預後方面發揮的關鍵作用。隨著癌症和遺傳疾病發病率的持續上升，NGS的應用預計將穩步成長，從而鞏固其作為美國醫療保健和生命科學生態系統中一項變革性技術的地位。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章美國次世代定序市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國次世代定序市場：分析工具
    • SWOT分析：依因素（政治、法律、經濟、技術）進行分析
    • 波特五力分析

第4章美國次世代定序市場：按技術分類的業務分析

  • 按變異分析和技術分類的次世代定序市場
  • 標靶定序、定序
  • 全基因測序
  • 全EXOME定序

第5章美國次世代定序市場：按產品分類的業務分析

  • 次世代定序市場：產品差異分析
  • 平台
  • 消耗品

第6章美國次世代定序市場：按應用領域分類的業務分析

  • 次世代定序市場：應用變異分析
  • 瘤
  • 臨床研究
  • 生殖健康
  • HLA型檢測/免疫系統監測
  • 總體基因體學、流行病學和藥物研發
  • 農業基因組學，法醫學
  • 消費者基因體學

第7章美國次世代定序市場：依工作流程進行業務分析

  • 次世代定序市場：工作流程差異分析
  • 前序
  • 定序
  • 數據分析

第8章美國次世代定序市場：按最終用途分類的業務分析

  • 次世代定序市場：最終用途差異分析
  • 學術研究
  • 臨床研究
  • 醫院和診所
  • 製藥和生物技術公司
  • 其他用戶

第9章 競爭情勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 市場情勢分析（2024年）
  • 市場參與企業概覽
    • Illumina, Inc
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific SE
    • Eurofins Scientific SE
    • QIAGEN
    • Quest Diagnostics Incorporated
    • Azenta Life Sciences (GENEWIZ)
    • NanoString
    • PacBio
    • bioMerieux
    • BGI Group
    • F. Hoffmann-La Roche Ltd
    • ARUP Laboratories
    • Novogene Co, Ltd.
    • Gene by Gene Ltd.
    • Lucigen Corporation
Product Code: GVR-4-68040-218-3

U.S. Next Generation Sequencing Market Summary

The U.S. next generation sequencing market size was estimated at USD 3.76 billion in 2024 and is projected to reach USD 16.75 billion by 2033, growing at a CAGR of 18.1% from 2025 to 2033. A robust presence of pharmaceutical, biotech entities, and research institutions drives next-generation sequencing (NGS) technology in the country. The market is propelled by increasing research and development (R&D) programs focusing on cancer, infectious diseases, and precision medicine. Moreover, genetic testing advancements are fueling NGS adoption in clinical labs for diagnosing rare conditions and guiding precision medicine.

Rising Incidence of Cancer and Genetic Disorders

The increasing prevalence of cancer, hereditary diseases, and complex genetic disorders in the U.S. is a significant driver of the NGS market. Next-generation sequencing enables early detection of genetic mutations and chromosomal abnormalities, facilitating timely diagnosis and personalized treatment planning. In oncology, NGS helps identify tumor-specific mutations, stratify patients for targeted therapies, and monitor disease progression or recurrence. It provides comprehensive genomic insights for rare and inherited disorders, supporting accurate diagnosis, carrier screening, and risk assessment for family members. Growing awareness among healthcare providers and patients about the benefits of genetic testing is further fueling adoption.

Moreover, initiatives such as newborn screening programs, prenatal genetic testing, and large-scale population genomics studies are expanding the use of NGS across clinical and research settings. The increasing demand for precision medicine, coupled with rising investment in genetic and genomic research, underscores the critical role of NGS in improving patient outcomes. As the incidence of cancer and genetic disorders continues to increase, the adoption of NGS is expected to grow steadily, solidifying its position as a transformative technology in the U.S. healthcare and life sciences ecosystem.

U.S. Next Generation Sequencing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. next generation sequencing market based on technology, product, application, workflow, and end use.

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Resequencing
    • DNA-based
    • RNA-based
  • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Platforms
    • Sequencing
    • Data Analysis
  • Consumables
    • Sample Preparation
    • Target Enrichment
    • Others
  • Application Outlook (Revenue, USD Million; 2021 - 2033)
  • Oncology
    • Diagnostics and Screening
    • Oncology Screening
    • Sporadic Cancer
    • Inherited Cancer
    • Companion Diagnostics
    • Other Diagnostics
    • Research Studies
  • Clinical Investigation
    • Infectious Diseases
    • Inherited Diseases
    • Idiopathic Diseases
    • Non-Communicable/Other Diseases
  • Reproductive Health
    • NIPT
    • Aneuploidy
    • Microdeletions
    • PGT
    • Newborn Genetic Screening
    • Single Gene Analysis
  • HLA Typing/Immune System Monitoring
  • Metagenomics, Epidemiology & Drug Development
  • Agrigenomics & Forensics
  • Consumer Genomics
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Pre-Sequencing
    • Nucleic Acid Extraction
    • Library Preparation
  • Sequencing
  • NGS Data Analysis
    • NGS Primary Data Analysis
    • NGS Secondary Data Analysis
    • NGS Tertiary Data Analysis
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharma & Biotech Entities
  • Other users

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Technology
    • 1.1.2. Product
    • 1.1.3. Application
    • 1.1.4. Workflow
    • 1.1.5. End-use
    • 1.1.6. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights

Chapter 3. U.S. Next Generation Sequencing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of cancer and genetic disorders
      • 3.2.1.2. Advancements in sequencing technologies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of computational efficiency for data management
      • 3.2.2.2. Non-value-based NGS reimbursement policy and regulation status
      • 3.2.2.3. Challenges associated with NGS implementation.
  • 3.3. U.S. Next Generation Sequencing Market Analysis Tools
    • 3.3.1. SWOT analysis; by factor (political & legal, economic, and technological)
    • 3.3.2. Porter's Five Forces Analysis

Chapter 4. U.S. Next Generation Sequencing Market: Technology Business Analysis

  • 4.1. Next Generation Sequencing Market: Technology Movement Analysis
  • 4.2. Targeted Sequencing & Resequencing
    • 4.2.1. Targeted Sequencing & Resequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
      • 4.2.1.1. DNA-based targeted sequencing & resequencing
        • 4.2.1.1.1. DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
      • 4.2.1.2. RNA-based targeted sequencing & resequencing
        • 4.2.1.2.1. RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • 4.3. Whole Genome Sequencing
    • 4.3.1. Whole Genome Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 4.4. Whole Exome Sequencing
    • 4.4.1. Whole Exome Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 5. U.S. Next Generation Sequencing Market: Product Business Analysis

  • 5.1. Next Generation Sequencing Market: Product Movement Analysis
  • 5.2. Platforms
    • 5.2.1. Platforms Market Estimates And Forecast, 2021 - 2033 (USD Million)
      • 5.2.1.1. Sequencing
        • 5.2.1.1.1. Sequencing platforms market estimates and forecast, 2021 - 2033 (USD Million)
      • 5.2.1.2. Data Analysis
        • 5.2.1.2.1. Data analysis platforms market estimates and forecast, 2021 - 2033 (USD Million
  • 5.3. Consumables
    • 5.3.1. Consumables market estimates and forecast, 2021 - 2033 (USD million)
    • 5.3.2. Sample Preparation
      • 5.3.2.1. Sample preparation market estimates and forecast, 2021 - 2033 (USD Million)
    • 5.3.3. Target Enrichment
      • 5.3.3.1. Target enrichment market estimates and forecast, 2021 - 2033 (USD Million)
    • 5.3.4. Others
      • 5.3.4.1. Others market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 6. U.S. Next Generation Sequencing Market: Application Business Analysis

  • 6.1. Next Generation Sequencing Market: Application Movement Analysis
  • 6.2. Oncology
    • 6.2.1. Oncology Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 6.2.2. Diagnostics & Screening
      • 6.2.2.1. Diagnostics & screening market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.2.2.2. Oncology screening
        • 6.2.2.2.1. Oncology screening market estimates and forecast, 2021 - 2033 (USD Million)
        • 6.2.2.2.2. Sporadic cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
        • 6.2.2.2.3. Inherited cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.2.2.3. Companion diagnostics
        • 6.2.2.3.1. Companion diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.2.2.4. Other diagnostics
        • 6.2.2.4.1. Other diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.2.3. Research Studies
      • 6.2.3.1. Research studies market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.3. Clinical investigation
    • 6.3.1. Clinical investigation market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.2. Infectious Diseases
      • 6.3.2.1. Infectious diseases market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.3. Idiopathic Diseases
      • 6.3.3.1. Idiopathic diseases market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.4. Inherited Diseases
      • 6.3.4.1. Inherited diseases market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.5. Non-Communicable/Other Diseases
      • 6.3.5.1. Non-communicable/other diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.4. Reproductive Health
    • 6.4.1. Reproductive Health Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 6.4.2. NIPT
      • 6.4.2.1. NIPT market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.4.2.2. Aneuploidy
        • 6.4.2.2.1. Aneuploidy market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.4.2.3. Microdeletions
        • 6.4.2.3.1. Microdeletions market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.3. PGT
      • 6.4.3.1. PGT market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.4. Newborn Genetic Screening
      • 6.4.4.1. Newborn genetic screening market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.5. Single Gene Analysis
      • 6.4.5.1. Single gene analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5. HLA Typing/Immune System Monitoring
    • 6.5.1. HLA Typing/Immune System Monitoring Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.6. Metagenomics, Epidemiology & Drug Development
    • 6.6.1. Metagenomics, Epidemiology & Drug Development Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.7. Agrigenomics & Forensics
    • 6.7.1. Agrigenomics & Forensics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.8. Consumer Genomics
    • 6.8.1. Consumer Genomics Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 7. U.S. Next Generation Sequencing Market: Workflow Business Analysis

  • 7.1. Next Generation Sequencing Market: Workflow Movement Analysis
  • 7.2. Pre sequencing
    • 7.2.1. Pre-Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
      • 7.2.1.1. Nucleic acid extraction
        • 7.2.1.1.1. Nucleic acid extraction market estimates and forecast, 2021 - 2033 (USD Million)
      • 7.2.1.2. Library preparation
        • 7.2.1.2.1. Library preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.3. Sequencing
    • 7.3.1. Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.4. Data Analysis
    • 7.4.1. Data Analysis Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.4.2. Primary Data NGS Analysis
      • 7.4.2.1. Primary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.3. Secondary Data Analysis
      • 7.4.3.1. Secondary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.4. Tertiary Data Analysis
      • 7.4.4.1. Tertiary data analysis market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 8. U.S. Next Generation Sequencing Market: End Use Business Analysis

  • 8.1. Next Generation Sequencing Market: End-use Movement Analysis
  • 8.2. Academic Research
    • 8.2.1. Academic Research Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.3. Clinical Research
    • 8.3.1. Clinical Research Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.4. Hospitals & Clinics
    • 8.4.1. Hospitals & Clinics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.5. Pharmaceutical & Biotech Entities
    • 8.5.1. Pharmaceutical & Biotech Entities Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.6. Other Users
    • 8.6.1. Other Users Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Market position analysis, 2024
  • 9.4. Participants Overview
    • 9.4.1. Illumina, Inc
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Thermo Fisher Scientific Inc.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Eurofins Scientific SE
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Eurofins Scientific SE
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. QIAGEN
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Quest Diagnostics Incorporated
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Azenta Life Sciences (GENEWIZ)
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. NanoString
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. PacBio
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. bioMerieux
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives
    • 9.4.11. BGI Group
      • 9.4.11.1. Company overview
      • 9.4.11.2. Financial performance
      • 9.4.11.3. Product benchmarking
      • 9.4.11.4. Strategic initiatives
    • 9.4.12. F. Hoffmann-La Roche Ltd
      • 9.4.12.1. Company overview
      • 9.4.12.2. Financial performance
      • 9.4.12.3. Product benchmarking
      • 9.4.12.4. Strategic initiatives
    • 9.4.13. ARUP Laboratories
      • 9.4.13.1. Company overview
      • 9.4.13.2. Financial performance
      • 9.4.13.3. Product benchmarking
      • 9.4.13.4. Strategic initiatives
    • 9.4.14. Novogene Co, Ltd.
      • 9.4.14.1. Company overview
      • 9.4.14.2. Financial performance
      • 9.4.14.3. Product benchmarking
      • 9.4.14.4. Strategic initiatives
    • 9.4.15. Gene by Gene Ltd.
      • 9.4.15.1. Company overview
      • 9.4.15.2. Financial performance
      • 9.4.15.3. Product benchmarking
      • 9.4.15.4. Strategic initiatives
    • 9.4.16. Lucigen Corporation
      • 9.4.16.1. Company overview
      • 9.4.16.2. Financial performance
      • 9.4.16.3. Product benchmarking
      • 9.4.16.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. next generation sequencing market, by technology, 2021 - 2033 (USD Million)
  • Table 4 U.S. next generation sequencing market, by product, 2021 - 2033 (USD Million)
  • Table 5 U.S. next generation sequencing market, by application, 2021 - 2033 (USD Million)
  • Table 6 U.S. next generation sequencing market, by workflow, 2021 - 2033 (USD Million)
  • Table 7 U.S. next generation sequencing market, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 U.S. next generation sequencing market: market outlook
  • Fig. 7 U.S. next generation sequencing competitive insights.
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook.
  • Fig. 10 Penetration and growth prospect mapping
  • Fig. 11 Industry value chain analysis
  • Fig. 12 U.S. next generation sequencing market driver impact
  • Fig. 13 U.S. next generation sequencing market restraint impact
  • Fig. 14 U.S. next generation sequencing market strategic initiatives analysis
  • Fig. 15 U.S. next generation sequencing market: Technology movement analysis
  • Fig. 16 U.S. next generation sequencing market: Technology outlook and key takeaways
  • Fig. 17 Targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Whole genome sequencing market estimates and forecast, 2021-2033 (USD Million)
  • Fig. 21 Whole exome sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 U.S. Next-generation sequencing market: Product outlook key takeaways
  • Fig. 23 U.S. Next-generation sequencing market: Product movement analysis
  • Fig. 24 Platforms market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Sequencing platforms market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Data analysis platforms market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Consumables market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Sample preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Target enrichment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. next generation sequencing Market: Application Movement Analysis
  • Fig. 32 U.S. next generation sequencing market: Application outlook and key takeaways
  • Fig. 33 Oncology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Diagnostics & screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Oncology screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 Sporadic cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 37 Inherited cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Companion diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Other diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Research studies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Clinical investigation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 42 Infectious diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 43 Idiopathic diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 Inherited diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Non-communicable/other diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Reproductive health market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 47 NIPT market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Aneuploidy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 49 Microdeletions market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 PGT market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 51 Newborn genetic screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Single gene analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 53 HLA typing/immune system monitoring market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Metagenomics, epidemiology & drug development market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 55 Agrigenomics & forensics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 56 Consumer genomics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 57 U.S. next generation sequencing market: workflow movement analysis
  • Fig. 58 U.S. next generation sequencing market: workflow outlook and key takeaways
  • Fig. 59 Pre-sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 Nucleic acid extraction market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 61 Library preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Automated library preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 63 Sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 64 Data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 65 Primary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 66 Secondary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 67 Tertiary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 U.S. Next generation sequencing market End Use outlook key takeaways
  • Fig. 69 U.S. Next-generation sequencing market: End Use movement analysis
  • Fig. 70 Academic research market estimates and forecast, 2021 - 2033 (USD Million))
  • Fig. 71 Clinical research market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 72 Hospitals & clinics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 73 Pharmaceutical & biotech entities market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 74 Other users market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 75 Market share of key market players- U.S. next generation sequencing market